In cancer, AKT1 has been found to be overexpressed in human gastric, breast and ovarian cancers; AKT2 was amplified and overexpressed in ovarian, pancreatic, hepatic, colorectal cancer and glioma, while AKT3 has been reported in progression of breast, prostate, ovarian cancer, and malignant melanoma [36,37,38,39]. This evidence concerns the gene AKT3 and ovarian carcinoma.